ATE394377T1 - Quinolinon- und benzoxazinon-derivate und ihren anwendungen - Google Patents

Quinolinon- und benzoxazinon-derivate und ihren anwendungen

Info

Publication number
ATE394377T1
ATE394377T1 AT04718298T AT04718298T ATE394377T1 AT E394377 T1 ATE394377 T1 AT E394377T1 AT 04718298 T AT04718298 T AT 04718298T AT 04718298 T AT04718298 T AT 04718298T AT E394377 T1 ATE394377 T1 AT E394377T1
Authority
AT
Austria
Prior art keywords
quinolinone
applications
benzoxazinone derivatives
benzoxazinone
derivatives
Prior art date
Application number
AT04718298T
Other languages
English (en)
Inventor
Ralph Harris
David Repke
Russell Stabler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE394377T1 publication Critical patent/ATE394377T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
AT04718298T 2003-03-11 2004-03-08 Quinolinon- und benzoxazinon-derivate und ihren anwendungen ATE394377T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45357403P 2003-03-11 2003-03-11

Publications (1)

Publication Number Publication Date
ATE394377T1 true ATE394377T1 (de) 2008-05-15

Family

ID=32990787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718298T ATE394377T1 (de) 2003-03-11 2004-03-08 Quinolinon- und benzoxazinon-derivate und ihren anwendungen

Country Status (23)

Country Link
US (2) US6943169B2 (de)
EP (1) EP1603880B1 (de)
JP (1) JP4404893B2 (de)
KR (1) KR100691090B1 (de)
CN (1) CN100455570C (de)
AR (1) AR043510A1 (de)
AT (1) ATE394377T1 (de)
AU (1) AU2004220388B9 (de)
BR (1) BRPI0408204A (de)
CA (1) CA2518403A1 (de)
CL (1) CL2004000450A1 (de)
CO (1) CO5601030A2 (de)
DE (1) DE602004013560D1 (de)
ES (1) ES2305742T3 (de)
HR (1) HRP20050775A2 (de)
MX (1) MXPA05009523A (de)
MY (1) MY135470A (de)
NO (1) NO20054135L (de)
NZ (1) NZ541642A (de)
RU (1) RU2333204C2 (de)
TW (1) TWI289141B (de)
WO (1) WO2004080969A1 (de)
ZA (1) ZA200506831B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US7592457B2 (en) * 2004-10-20 2009-09-22 Korea Research Institute Of Chemical Technology 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
RU2497819C2 (ru) * 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
WO2009009135A1 (en) * 2007-07-11 2009-01-15 Dow Corning Corporation Compositions for delivering a drug
EP2254564A1 (de) 2007-12-12 2010-12-01 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2163541A1 (de) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazin-Derivate zur Bindung und Abbildung von Amyloidplaques und deren Verwendung
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN114085179B (zh) * 2021-11-29 2024-05-03 福建科宏生物工程股份有限公司 一种n-乙酰基-5-甲氧基色胺的制备方法
CA3254867A1 (en) * 2022-03-30 2023-10-05 University Of Florida Research Foundation, Incorported COMPOUNDS FOR THE TREATMENT OF PSYCHOSTIMULANT MISUSE
WO2024163956A2 (en) * 2023-02-03 2024-08-08 University Of Florida Research Foundation, Incorporated Sigma receptor ligand compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733321A (en) 1971-07-06 1973-05-15 Squibb & Sons Inc 1,4-benzothiazin-3-ones
US4078062A (en) 1976-10-28 1978-03-07 E. R. Squibb & Sons, Inc. Substituted 2H-1,4-benzothiazin-3(4H)-ones
AU594983B2 (en) * 1985-10-29 1990-03-22 Dainippon Pharmaceutical Co. Ltd. Novel quinoline derivatives and processes for preparation thereof
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL133870A0 (en) * 1997-07-11 2001-04-30 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
BR9815785A (pt) 1998-03-31 2000-12-05 Warner Lambert Co Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina
HUP0101699A3 (en) 1998-03-31 2002-05-28 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors and pharmaceutical compositions containing the same
PL343112A1 (en) 1998-03-31 2001-07-30 Warner Lambert Co Quinolones as serine protease inhibitors
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
EP1255743A1 (de) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-dihydro-2h-benzo[1,4]oxazine als faktor xa inhibitoren
AU2001234705A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indalone and benzimidazolone inhibitors of factor xa
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
ES2271124T3 (es) * 2000-11-24 2007-04-16 Smithkline Beecham Plc Compuestos indolil-sulfonilicos utiles en el tratamiento de trastornos del snc.
RU2268884C2 (ru) * 2001-08-10 2006-01-27 Ф.Хоффманн-Ля Рош Аг Арилсульфонильные производные, обладающие сродством к рецептору 5-ht6, и способ их получения
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物

Also Published As

Publication number Publication date
EP1603880B1 (de) 2008-05-07
CN1759101A (zh) 2006-04-12
BRPI0408204A (pt) 2006-02-14
MXPA05009523A (es) 2005-10-18
KR100691090B1 (ko) 2007-03-12
AU2004220388A1 (en) 2004-09-23
NZ541642A (en) 2008-03-28
CL2004000450A1 (es) 2005-01-07
AR043510A1 (es) 2005-08-03
AU2004220388B2 (en) 2009-12-10
US7476675B2 (en) 2009-01-13
AU2004220388B9 (en) 2010-01-07
ZA200506831B (en) 2006-06-28
TW200424189A (en) 2004-11-16
RU2005131172A (ru) 2006-05-10
NO20054135D0 (no) 2005-09-06
HRP20050775A2 (en) 2006-10-31
MY135470A (en) 2008-04-30
US20050261308A1 (en) 2005-11-24
CN100455570C (zh) 2009-01-28
ES2305742T3 (es) 2008-11-01
NO20054135L (no) 2005-09-23
WO2004080969A1 (en) 2004-09-23
JP4404893B2 (ja) 2010-01-27
US6943169B2 (en) 2005-09-13
JP2006515344A (ja) 2006-05-25
DE602004013560D1 (de) 2008-06-19
KR20050109078A (ko) 2005-11-17
RU2333204C2 (ru) 2008-09-10
US20040186092A1 (en) 2004-09-23
EP1603880A1 (de) 2005-12-14
CA2518403A1 (en) 2004-09-23
CO5601030A2 (es) 2006-01-31
TWI289141B (en) 2007-11-01

Similar Documents

Publication Publication Date Title
DE602004013560D1 (de) Quinolinon- und benzoxazinon-derivate und ihren anwendungen
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
ATE521638T1 (de) Gegen angiopoietin-2 gerichtete antikörper und anwendungen davon
EP1781098A4 (de) Antimikrobielle geräte und zusammensetzungen
ATE472534T1 (de) Benzimidazolderivate: herstellung und pharmazeutische anwendungen
DE602004030308D1 (de) HF-Messer und Endoskopiegerät
EP1676215A4 (de) Dienst-discovery und publikation
ATE422495T1 (de) Antibakterielle naphthydrin- und quinolinderivate
DE502004009028D1 (de) Scheinwerfer und Scheinwerferelement
ATE471937T1 (de) Cyclopropylgruppensubstituierte oxazolidinonantibiotika und derivate davon
EP1874143A4 (de) Reithose und herstellungsverfahren dafür
DE602006010513D1 (de) Kondensator-lüfter-anordnung und steuerverfahren dafür
DE602005003077D1 (de) Befestigung und Knopf
DE602005022751D1 (de) Gleitelement und herstellungsverfahren dafür
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
ATE455755T1 (de) Tetralin- und indanderivate und deren anwendungen
DE10338270B4 (de) Variator und Variatoranordnung
ATE442368T1 (de) 3-amino-2-arylpropylazaindole und anwendungen davon
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DE602005025107D1 (de) Arylamin-zusammensetzung und organische elektrolumineszenzeinrichtung
EP2227485A4 (de) Resistenzgen und anwendungen davon
DE602004029488D1 (de) Leuchtstoffschirm und abbildungsbaugruppe
DE502004000216D1 (de) Doppelkupplungseinrichtung und Radiallagerungskonzept hierfür
DE602004031056D1 (de) Anti-nebel-einrichtung und aussenspiegel
DE602005022896D1 (de) Benzoxazin- und chinoxalinderivate und anwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1603880

Country of ref document: EP

REN Ceased due to non-payment of the annual fee